Funding for this research was provided by:
Grand Challenges Canada (S4_0280-01, TTS-0709-05)
European and Developing Countries Clinical Trials Partnership (TMA2016CDF-1545)
Text and Data Mining valid from 2018-10-03
Received: 8 March 2018
Accepted: 23 September 2018
First Online: 3 October 2018
Ethics approval and consent to participate
: This study obtained ethical approval and clearance from the School of Biomedical Sciences Institutional Review and Ethics Committee (IREC), College of Health Sciences, Makerere University, Kampala, UG (Protocol Approval #s: SBS 138 and 228); as well as the Uganda National Council of Science and Technology (UNCST; Protocol Clearance # HR 1521). All samples used were broadly consented for future use, and a waiver consent was obtained from the Institutional Review and Ethics Committee (IREC) to re-use them in this work <i>The patient data were appropriately de-identified and anonymised, hence waiver of need for consent by the UVRI-Directorate and the SBS-IREC.</i>
: “Not Applicable”. This study used stored samples for which waiver approval was obtained.
: MW has filed a PCT for these epitopes and derivative PAbs and Mabs (see: Wayengera M. Conserved B cell epitopes of filovirus glycoprotein and their use as either biomarkers or therapeutics and sub-unit vaccines for Ebola virus and marburg virus International Application #:PCT/IB2014/066251; Pub #:WO/2016/079572; Date:26.05.2016; Filing Date:21.11.2014). MW is Chief Scientific Officer at Restrizymes Biotherapeutics (U) LTD—a Ugandan start-up biotech.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.